Hype vs. reality: What pharma’s hottest R&D bets have actually proved
Source: BioPharma Dive - Latest News
New types of bispecifics, antibod-drug conjugates and cell therapies haven’t yet themselves in the clinic. Pharmaceutical companies are betting billions anyway.